BRAF and melanoma: Indeed, our results demonstrate that the binding of methiothepin to Ptch1 increases the cytotoxicity of five different chemotherapeutic drugs (doxorubicin, cisplatin, oxaliplatin, vemurafenib and trametinib) against various melanoma cell lines carrying or not a BRAF mutation.